Journals on Biomedical Science - BJSTR Journal

Abstract

Hepatitis C virus (HCV) infection is associated with increased rates of glucose abnormalities, including diabetes #mellitus and insulin resistance. The presence of glucose abnormalities in HCV infected patients, including diabetes mellitus and insulin resistance, is associated with negative liver-related outcomes (i.e., severe liver fibrosis, decreased response to antivirals, and increased the occurrence of #hepatocellular carcinoma) [1]. It is suggested that circulating micro #ribonucleic acid (miRNA) can perform regulatory functions to modulate gene expression in peripheral tissues leading to insulin resistance and diabetes. Once miRNA of HCV cleared by treatment, insulin resistance and glucose metabolism improved [2]. A fixed-dose combination of the hepatitis C virus NS5B #polymerase inhibitor #sofosbuvir, the HCV NS5A inhibitor #velpatasvir and the HCV NS3/4A protease inhibitor voxilaprevir is approved in Europe for the treatment of chronic HCV infection in adults [3]. Here we present a case of HCV patient treated with #sofosbuvir/velpatasvir/ voxilaprevir that lead to improvement of his hemoglobin A1c (HbA1c) in addition to a significant reduction of his daily insulin dose.

 For more articles on BJSTR Journal please click on https://biomedres.us/

For more Biomedical Science Articles on BJSTR

https://biomedres.us/fulltexts/BJSTR.MS.ID.001792.php

Treatment of Hepatitis C with Sofosbuvir, Velpatasvir and Voxilaprevir Decreases Hemoglobin A1c and Dependence on Anti-Glycemic Medications  by Kashif Aziz in BJSTR